Evidence map›Paper›PMID 39866935›Full record

ArticleEJHaem2025

Pneumonia in patients with chronic lymphocytic leukemia treated with venetoclax-based regimens: A real-world analysis of Polish Adult Leukemia Group (PALG).

Elżbieta Kalicińska, Paula Jablonowska-Babij, Marta Morawska, Elżbieta Iskierka-Jażdżewska, Joanna Drozd-Sokolowska, Ewa Paszkiewicz-Kozik, Łukasz Szukalski, Judyta Strzała, Urszula Gosik, Jakub Dębski and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Elżbieta KalicińskaClinical Department of Hematology, Cell Therapies and Internal Diseases Wroclaw Medical University Wroclaw Poland.ORCID https://orcid.org/0000-0002-4797-8001
Paula Jablonowska-BabijClinical Department of Hematology, Cell Therapies and Internal Diseases Wroclaw Medical University Wroclaw Poland.
Marta MorawskaExperimental Hematooncology Department Medical University of Lublin Lublin Poland.
Elżbieta Iskierka-JażdżewskaDepartment of General Hematology Medical University of Lodz Lublin Poland.ORCID https://orcid.org/0000-0003-2772-8870
Joanna Drozd-SokolowskaDepartment of Hematology, Transplantation and Internal Medicine Medical University of Warsaw Warsaw Poland.
Ewa Paszkiewicz-KozikDepartment of Lymphoid Malignancies National Research Institute of Oncology Warsaw Poland.
Łukasz SzukalskiDepartment of Hematology Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń Toruń Poland.
Judyta StrzałaDepartment of Hematology and Bone Marrow Transplantation Pomeranian Hospitals in Gdynia Gdynia Poland.
Urszula GosikDepartment of Hematology St. John's Cancer Center in Lublin Lublin Poland.
Jakub DębskiDepartment of Hematology Provincial Specialist Hospital in Legnica Legnica Poland.
Iga AndrasiakIndependent Researcher Wroclaw Poland.
Anna SkotnyHarvard T.H. Chan School of Public Health - ECPE Boston Massachusetts USA.
Krzysztof JamroziakDepartment of Hematology, Transplantation and Internal Medicine Medical University of Warsaw Warsaw Poland.ORCID https://orcid.org/0000-0001-7207-8534
Tomasz WrobelClinical Department of Hematology, Cell Therapies and Internal Diseases Wroclaw Medical University Wroclaw Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections that can affect their clinical outcomes. Aims: To assess: (1) the incidence of pneumonia in CLL patients treated with venetoclax-based regimens in a real-world setting, (2) the risk factors for event-free survival (EFS), and (3) overall survival (OS). Methods: This multicenter study included 322 patients from eight centers. Univariable and multivariable analyses (MVA) were performed, having the development of pneumonia during venetoclax-based treatment and OS as outcomes. Results: The most common complication was neutropenia (59%). During treatment with venetoclax-based regimens, 66 (20%) of patients developed pneumonia: 50 (23%) patients in the rituximab plus venetoclax (R-VEN) group, 13 (16%) patients in the obinutuzumab plus venetoclax (O-VEN) group ( Conclusions: Our real-world study showed that pneumonia during venetoclax treatment occurs more frequently than reported in registration trials and has a negative impact on OS, especially in patients with R/R CLL treated with R-VEN. Neutropenia is not a risk factor for pneumonia.

Indexed as

CLLinfectionoverall survivalpneumoniavenetoclax

Identifiers

PMID39866935
PMCPMC11756990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.